<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microenvironmental factors play a critical role in B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Most studies emphasize the role of <z:hpo ids='HP_0002665'>lymphoma</z:hpo>-infiltrating T-cells and macrophages, with few studies on natural killer cells </plain></SENT>
<SENT sid="2" pm="."><plain>Natural killer cells include a less mature (CD56(bright)/CD16-) subset that is more common in lymph nodes and a more mature (CD56(dim)/CD16+) subset that is more numerous in peripheral blood </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, the proportions of natural killer cells, natural killer subsets, and natural killer-like T-cells (CD3+, CD56+, and/or CD16/57+) were determined by flow cytometry in 150 cases of tissue-based B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and 89 nonneoplastic tissue biopsies </plain></SENT>
<SENT sid="4" pm="."><plain>Results were correlated with the clinicopathologic findings </plain></SENT>
<SENT sid="5" pm="."><plain>A higher percentage of natural killer cells was found in nonneoplastic spleen versus other nonneoplastic tissue (P &lt; .001), in splenic-based B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> versus other B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P &lt; .01), and in stage II to IV diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> versus stage I diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 19, P = .02) </plain></SENT>
<SENT sid="6" pm="."><plain>The more mature natural killer subset was increased in benign spleen (P &lt; .001) and nonsplenic B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P &lt; .01) versus nonsplenic, nonneoplastic tissue; in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> versus other B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P &lt; .001); and in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with an intermediate follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> international prognostic index score (n = 17, P = .04) </plain></SENT>
<SENT sid="7" pm="."><plain>A higher proportion of natural killer-like T-cells was seen in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> versus other B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (P = .001), whereas <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> contained fewer natural killer-like T-cells (P &lt; .001) </plain></SENT>
<SENT sid="8" pm="."><plain>The proportions of natural killer cells, natural killer subsets, and natural killer-like T-cells vary with tissue site, type of B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and clinical stage in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>A higher proportion of CD56(dim)/CD16/57+ natural killer cells is found in spleen, in more aggressive B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with an intermediate follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> international prognostic index score </plain></SENT>
<SENT sid="10" pm="."><plain>This may be of importance with increasing therapeutic use of immunomodulatory agents </plain></SENT>
</text></document>